Greywolf Therapeutics HLA-E program

Greywolf Therapeutics is developing a preclinical small molecule program focused on modulating the peptide repertoire presented by non-classical HLA-E molecules. The technology leverages the inhibition of Endoplasmic Reticulum Aminopeptidase (ERAP) enzymes, specifically ERAP1 and ERAP2, which play a critical role in processing peptides for MHC Class I presentation. By altering the peptides displayed on HLA-E, the therapy is designed to overcome immune evasion mechanisms in solid tumors and chronic viral infections, potentially making these cells visible to the immune system. This program is currently in the discovery and validation phase and aims to uncover novel antigens that can be recognized by the immune system to trigger a therapeutic response.

Other names

HLA-E small molecule modulatorERAP-mediated HLA-E peptide repertoire modulator